HST
42
-3
PPL
52
-3
PLD
48
-3
CCI
36
2
UAL
77
-8
WY
37
-2
CF
48
3
NWL
57
-3
BK
74
3
CI
42
-3
FRT
53
-3
AES
57
13
V
36
-4
EW
60
7
CTAS
28
-3
AIZ
52
2
TSN
43
-4
VZ
55
5
GD
60
3
OXY
40
3
HST
42
-3
PPL
52
-3
PLD
48
-3
CCI
36
2
UAL
77
-8
WY
37
-2
CF
48
3
NWL
57
-3
BK
74
3
CI
42
-3
FRT
53
-3
AES
57
13
V
36
-4
EW
60
7
CTAS
28
-3
AIZ
52
2
TSN
43
-4
VZ
55
5
GD
60
3
OXY
40
3
Financhill
Back

Pacira Biosciences, Inc. 10K Form

Sell
48

PCRX
Pacira Biosciences, Inc.

Last Price:
$24.21
Seasonality Move:
14.62%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive PCRX News And Ratings

See the #1 stock for the next 7 days that we like better than PCRX

PCRX Financial Statistics

Sales & Book Value

Annual Sales: $701M
Cash Flow: $57M
Price / Cash Flow: 8.95
Annual Sales: $16.93
Price / Book: 1.42

Profitability

EPS (TTM): 0.44610
Net Income (TTM): $21.4M
Gross Margin: $473.3M
Return on Equity: 2.81%
Return on Assets: 1.43%

Pacira Biosciences, Inc. Earnings Forecast

Key Pacira Biosciences, Inc. Financial Ratios

  • The Gross Profit Margin over the past 18 years for PCRX is 67.51%.
  • The Selling, General & Administrative Expenses for PCRX have been equal to 36.98% of Gross Profit Margin.
  • The Research & Development expenses have been 11.64% of Revenue.
  • The Net Earning history of PCRX is -14.20% of Total Revenues.
  • Per Share Earnings over the last 18 years have been positive in 9 years.

Pacira Biosciences, Inc. Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceuticals
Sector: Health Care
Current Symbol: PCRX
CUSIP: 695127
Website: pacira.com

Debt

Debt-to-Equity Ratio: 0.58
Current Ratio: 5.26
Quick Ratio: 3.38

Price-to-Earnings

Trailing P/E Ratio: 28.52
Forward P/E Ratio: 7.12

PCRX Technical Analysis vs Fundamental Analysis

Sell
48
Pacira Biosciences, Inc. (PCRX) is a Sell

Is Pacira Biosciences, Inc. a Buy or a Sell?